In phase 1 clinical trial (NCT03019055), administration of bispecifc CD19/20-CAR-T cells resulted in CR among 64% and PR in 18% of NHL and ALL patients, simultaneously showing low toxicity [112]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.